We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | NASDAQ:ARQT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.38% | 7.81 | 7.81 | 7.82 | 8.1399 | 7.81 | 7.92 | 874,035 | 18:03:17 |
From Nov 2023 to May 2024
By Ben Glickman
Shares of Arcutis Biotherapeutics rose late Friday after the company's treatment for a skin condition was approved by the Food and Drug Administration.
The stock was up 18% to $2.89 in after-hours trading, following a 3.9% drop at Friday's close. Shares are down about 84% this year.
Zoryve topical foam has been approved for the treatment of seborrheic dermatitis, a skin condition which mostly affects the scalp, the Westlake Village, Calif.-based dermatology company said.
A cream form of Zoryve was already approved by the FDA for the topical treatment of plaque psoriasis in patients 6 years of age and older. Net product revenues for the cream were $8.1 million in the third quarter, Arcutis reported last month.
Arcutis said it plans to make the topical foam widely available by the end of next month.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:58 ET (22:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Arcutis Biotherapeutics Chart |
1 Month Arcutis Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
